PBAC's latest decision on Diphtheria, tetanus, acellular pertussis vaccine (dtpa): Noted (2016). Considered for Immunisation of women in the third trimester of every pregnancy to reduce pertussis disease in the mother and early onset infant disease.
PBAC outcome
Noted
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Pregnant women in the third trimester of every pregnancy.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Registry
Primary endpoint
Vaccine effectiveness (VE) in preventing pertussis in infants and mothers
Cost-effectiveness analysis performed but ICER value commercially sensitive/redacted ('$'''''''); submission compared cost-effectiveness against no vaccination but numeric ICER not disclosed in public text.